Growth differentiation factor‐15, treatment with liraglutide, and clinical outcomes among patients with heart failure
Abstract Aims Associations between growth differentiation factor‐15 (GDF‐15), cardiovascular outcomes, and exercise capacity among patients with a recent hospitalization for heart failure (HHF) and heart failure with reduced ejection fraction (HFrEF) are unknown. We utilized data from the ‘Functiona...
Main Authors: | Abhinav Sharma, Stephen Greene, Muthiah Vaduganathan, Marat Fudim, Andrew P. Ambrosy, Jie‐Lena Sun, Steven E. McNulty, Adrian F. Hernandez, Barry A. Borlaug, Eric J. Velazquez, Robert J. Mentz, Adam D. DeVore, Brooke Alhanti, Kenneth Margulies, G. Michael Felker |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-08-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.13348 |
Similar Items
-
High-Dose Liraglutide and SGLT2 Inhibitor: A Promising Combination
by: Marvin Wei Jie Chua
Published: (2021-12-01) -
Effects of liraglutide on obesity-associated functional hypogonadism in men
by: M Jensterle, et al.
Published: (2019-02-01) -
Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride
by: J. Jendle, et al.
Published: (2021-12-01) -
Fabrication and Evaluation of a pH-Responsive Nanocomposite-Based Colonic Delivery System for Improving the Oral Efficacy of Liraglutide
by: Song JG, et al.
Published: (2023-07-01) -
Efficacy and safety of liraglutide in Indian adolescents with obesity
by: I. S. Kochar, et al.
Published: (2019-06-01)